Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$45.46M+74317.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gary S. Gillheeney
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 854
- Beta
- 1.27
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.42
Financials
Revenue
$45.46M+74317.2%Net Income
$-29.63MEBITDA
$-25.20MFree Cash Flow
$-20.06MEPS (diluted)
$-0.25Shares Outstanding (diluted)
128.99M+1528.7%Operating Expenses
$53.05MCash & Debt
$21.33MReturn of Capital
$9.21MRevenue by Segment (annual)
$564.17MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $563.03M | $37.03M | $0.16 |
| 2024 | $482.04M | $861.0K | $-0.01 |
| 2023 | $433.14M | $4.95M | $0.04 |
| 2022 | $450.89M | $15.53M | $0.12 |
| 2021 | $467.36M | $94.20M | $0.73 |
| 2020 | $338.30M | $17.23M | $0.16 |
| 2019 | $260.98M | $-38.71M | $-0.44 |
| 2018 | $193.45M | $-64.83M | $-0.94 |
| 2017 | $0.00 | $-2.09M | $-0.03 |
| 2016 | $0.00 | $-208.7K | $-0.02 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.43
- Implied price
- $13.74
- Return from $0.77
- 77.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $6.83 — today's price is already 88.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 22 | 27 | 32 | 37 | 42 |
|---|---|---|---|---|---|
| -2.0% | 49.7% | 56.0% | 61.4% | 66.2% | 70.4% |
| 3.0% | 57.4% | 64.0% | 69.6% | 74.6% | 79.1% |
| 8.0% | 65.0% | 71.9% | 77.9% | 83.1% | 87.8% |
| 13.0% | 72.7% | 79.9% | 86.1% | 91.6% | 96.5% |
| 18.0% | 80.3% | 87.8% | 94.3% | 100.1% | 105.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
146+4.17%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·16d ago·Neutral
Organogenesis Holdings Inc. (ORGO) Q3 2026 Earnings Call Transcript Organogenesis Holdings Inc. ( ORGO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Gary Gillheeney - President, CEO, Chair of the Board David Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Welcome, ladies and gentlemen, to the Third Quarter 2026 Earnings Conferenc…
View source ↗ - Newsfool.com·16d ago·Neutral
Organogenesis: 3 Key Takeaways for Long-Term Investors Organogenesis increased third quarter net product revenue 6% quarter over quarter. Management expects annual operating expense reductions of approximately $45 million.
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Organogenesis Q3 Earnings Call Highlights Organogenesis NASDAQ: ORGO reported a 70% year-over-year decline in third-quarter net product revenue and lowered the upper end of its full-year revenue outlook as the skin substitute market recovered more slowly than management had anticipated.
View source ↗ - Newsglobenewswire.com·41d ago·Negative
…onstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE1, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly®AM (PCMP) plus standard of ca…
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
… Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that third quarter of fiscal year 2026 financial results will be reported after the ma…
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise -42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.25 vs $-0.17miss
- Thu, Aug 6$-0.71 vs $-0.35miss
- Thu, May 7$-0.37 vs $-0.29miss
- Thu, Feb 26$0.31 vs $0.21beat
- Thu, Nov 6$0.18 vs $0.21miss
- Thu, Aug 7$-0.09 vs $0.07miss
Estimates and results for ORGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ORGO officers and directors.
- Bought
- $1.9m
- Sold
- $2.7m
7 trades
6 trades
- Leibowitz Arthur Sbought
- Driscoll Michael Josephbought
- Nussdorf Glenn Hsold
- Nussdorf Glenn Hsold
- Nussdorf Glenn Hsold
- Nussdorf Glenn Hsold
- Nussdorf Glenn Hsold
- Nussdorf Glenn Hsold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ORGO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
